Lifecore Biomedical, Inc. (LFCR)
(Delayed Data from NSDQ)
$4.85 USD
-0.08 (-1.62%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $4.84 -0.01 (-0.21%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth F Momentum A VGM
Cash flow Statements
Fiscal Year End for Lifecore Biomedical, Inc falls in the month of May.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
5/31/2024 | 5/31/2023 | 5/31/2022 | 5/31/2021 | 5/31/2020 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 12.01 | -99.56 | -97.43 | -32.67 | -38.19 |
Depreciation/Amortization & Depletion | 8.86 | 14.59 | 78.68 | 19.87 | 18.84 |
Net Change from Assets/Liabilities | -3.85 | 20.03 | -6.60 | 8.89 | -27.66 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -17.24 | 47.51 | 0.96 | 18.93 | 29.97 |
Net Cash From Operating Activities | -0.22 | -17.44 | -24.40 | 15.02 | -17.04 |
Property & Equipment | -17.92 | -21.48 | -26.99 | -10.86 | -24.25 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 16.67 | 73.50 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 45.10 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | -9.84 | 0.00 | 0.36 |
Net Cash from Investing Activities | -17.92 | -4.81 | 81.77 | -10.86 | -23.89 |
Uses of Funds
5/31/2024 | 5/31/2023 | 5/31/2022 | 5/31/2021 | 5/31/2020 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.72 | 42.90 | 0.00 | 0.00 | 0.03 |
Issuance (Repayment) of Debt | 4.29 | 26.31 | -66.41 | 55.87 | 16.38 |
Increase (Decrease) Short-Term Debt | 2.88 | -23.19 | 11.00 | -48.40 | 25.40 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.38 | -6.32 | -1.61 | -10.89 | -1.79 |
Net Cash from Financing Activities | 7.51 | 39.70 | -57.02 | -3.42 | 40.02 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -10.63 | 17.45 | 0.35 | 0.74 | -0.91 |
Cash at Beginning of Period | 19.09 | 1.64 | 1.30 | 0.55 | 1.47 |
Cash at End of Period | 8.46 | 19.09 | 1.64 | 1.30 | 0.55 |
Diluted Net EPS | 0.32 | -3.32 | -3.31 | -1.12 | -1.31 |
Fiscal Year End for Lifecore Biomedical, Inc falls in the month of May.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
8/31/2024 | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 12.01 | 19.10 | 3.46 | -10.75 |
Depreciation/Amortization & Depletion | NA | 8.86 | 6.61 | 4.37 | 2.17 |
Net Change from Assets/Liabilities | NA | -3.85 | -8.40 | -3.62 | -4.20 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | -17.24 | -26.16 | -11.55 | 4.46 |
Net Cash From Operating Activities | NA | -0.22 | -8.86 | -7.32 | -8.33 |
Property & Equipment | NA | -17.92 | -15.28 | -9.03 | -5.05 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -17.92 | -15.28 | -9.03 | -5.05 |
Uses of Funds
8/31/2024 | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.72 | 0.72 | 0.72 | 0.72 |
Issuance (Repayment) of Debt | NA | 4.29 | -0.48 | -0.25 | -0.03 |
Increase (Decrease) Short-Term Debt | NA | 2.88 | 3.10 | 0.07 | 2.28 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.38 | 4.78 | -0.06 | -0.05 |
Net Cash from Financing Activities | NA | 7.51 | 8.12 | 0.49 | 2.93 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -10.63 | -16.02 | -15.87 | -10.45 |
Cash at Beginning of Period | NA | 19.09 | 19.09 | 19.09 | 19.09 |
Cash at End of Period | NA | 8.46 | 3.07 | 3.22 | 8.64 |
Diluted Net EPS | NA | -0.14 | 0.42 | 0.39 | -0.35 |